Victory Capital Management Inc. Has $17.41 Million Stake in Vital Therapies Inc (VTL)
Victory Capital Management Inc. lifted its stake in shares of Vital Therapies Inc (NASDAQ:VTL) by 12.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,925,886 shares of the company’s stock after buying an additional 322,797 shares during the quarter. Victory Capital Management Inc. owned about 0.07% of Vital Therapies worth $17,409,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of VTL. Goldman Sachs Group Inc. raised its stake in Vital Therapies by 261.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after purchasing an additional 168,705 shares in the last quarter. Granahan Investment Management Inc. MA raised its stake in Vital Therapies by 51.4% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after purchasing an additional 131,828 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in Vital Therapies in the 2nd quarter worth about $268,000. Dowling & Yahnke LLC acquired a new stake in Vital Therapies in the 3rd quarter worth about $252,000. Finally, New York State Common Retirement Fund acquired a new stake in Vital Therapies in the 3rd quarter worth about $213,000. Institutional investors own 25.00% of the company’s stock.
VTL has been the subject of several analyst reports. Raymond James Financial reiterated a “buy” rating on shares of Vital Therapies in a research note on Tuesday, December 5th. BidaskClub upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, ValuEngine upgraded shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. Vital Therapies presently has an average rating of “Hold” and a consensus target price of $6.00.
In other news, Director Muneer A. Satter bought 50,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was bought at an average cost of $4.77 per share, for a total transaction of $238,500.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Muneer A. Satter bought 150,000 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was purchased at an average price of $4.89 per share, with a total value of $733,500.00. The disclosure for this purchase can be found here. Insiders bought a total of 300,000 shares of company stock valued at $1,520,000 over the last 90 days. Corporate insiders own 32.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2018/02/13/victory-capital-management-inc-has-17-41-million-stake-in-vital-therapies-inc-vtl.html.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Want to see what other hedge funds are holding VTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vital Therapies Inc (NASDAQ:VTL).
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.